• Mashup Score: 0

    For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list. The FDA first noted the fludarabine shortage in May, with four of its manufacturers reporting either backordered or limited supplies available as of October.

    Tweet Tweets with this article
    • SHORTAGE: Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT. https://t.co/jQj8o5p9MK #MedicationShortage #Fludarabine @US_FDA @MedicalCollege #HemOnc #OncAlert

  • Mashup Score: 0

    THIS WEEK at a glance:CART and IFNgammaR pathway for solid tumorsTisacel has 50% CR for primary CNVS lymphomaInfectious complications after anti-BCMA CARTsFludarabine exposure and CART efficacy for leukemiaMachine learning score to predict allogeneic donor mobilizationSocial and racial disparities matter in CART therapy access

    Tweet Tweets with this article
    • Read my latest: “Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 14/04/2022- Issue #4” https://t.co/nkPgLI2jZg #CART #alloHCT #infections #fludarabine #racialdisparities #CNSlymphoma

  • Mashup Score: 0
    JNCCN 360 - 4 year(s) ago

    By: Lauren Harrison, MS Posted: Wednesday, June 17, 2020 The 1-year overall survival among elderly patients with acute myeloid leukemia (AML) appears to be prolonged with azacitidine compared with fludarabine plus cytarabine; however long-term outcomes are poor with both treatment protocols. Susana Vives Polo,…

    Tweet Tweets with this article
    • #EHA25Virtual: #azacitidine vs. #fludarabine plus #cytarabine in elderly patients with #AML: https://t.co/JD0mJjmITq #leusm #JNCCN360 https://t.co/i7SX5l0SX8